Compare AbbVie Inc (ABBV) vs KraneShares CSI China Internet ETF (KWEB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs KraneShares CSI China Internet ETF — how do they compare? AbbVie Inc trades at $252.5 (market cap $449.91B), while KraneShares CSI China Internet ETF trades at $26.52. The key difference: AbbVie Inc pays a 2.72% dividend while KraneShares CSI China Internet ETF pays none, and AbbVie Inc is trading nearer its 52-week high, KraneShares CSI China Internet ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | KWEB | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Sector/Thematic |
52-Week High | $261.07 | $42.94 |
52-Week Low | $184.85 | $23.63 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.65, down 0.04% on the day, with a bullish technical signal supported by moving averages. The company has beaten earnings expectations for three consecutive quarters, with Q2 2026 EPS expected at $3.79. Recent positive Phase 2 data for ELAHERE in ovarian cancer and strong institutional buying activity highlight growth momentum. Valuation metrics appear elevated with a P/E of 124.83 and P/B of 245.29, though the company maintains a robust gross margin of 70.68% and consistent dividend payments.
The outlook remains positive with analyst consensus at 'Buy' and a $266.33 price target, representing 4.6% upside. Key opportunities include Skyrizi and Rinvoq growth offsetting Humira declines, while risks include high debt levels, patent cliffs in the 2030s, and elevated valuation multiples that could pressure returns if growth slows.
KWEB, the KraneShares CSI China Internet ETF, trades at $25.59, up 2.44% on the day, with a bullish technical signal from moving averages but neutral oscillators. The ETF offers concentrated exposure to Chinese internet and AI companies, currently near 52-week lows, benefiting from AI-driven growth and government support. Recent news highlights China's factory rebound and substantial AI infrastructure investments.
The outlook for KWEB is mixed; attractive valuations and AI tailwinds present opportunities, but risks include US-China tensions and China's economic volatility. Analyst sentiment is cautious due to geopolitical and regulatory uncertainties, though long-term growth potential in Chinese tech remains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About KraneShares CSI China Internet ETF
KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.
Read more on KWEB →
